HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced today that the prime-boost investigational vaccine regimen was safe and 31 percent effective in preventing HIV infection.
"These new findings represent an important step forward in HIV vaccine research," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, which provided major funding and other support for the study. "For the first time, an investigational HIV vaccine has demonstrated some ability to prevent HIV infection among vaccinated individuals. Additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection, but certainly this is an encouraging advance for the HIV vaccine field.
"We thank the trial staff in Thailand and the United States for their years of effort in successfully conducting this study and the study participants and the people of Thailand for their long-standing support of HIV vaccine research," Dr. Fauci adds.
Recent Comments
-
By the way, know what? I said the whole "risk to being reduced to pets" was an idle question, but if you want me to play at this game, I will...
-
Don't want to hijack this thread in a Randian apologia direction, especially since I do find her elitism more than a bit off-putting (though I do...
-
>If we can't define intelligence then the project of attempting to create it will always be incoheren
No, we can't define exactly...
-
Have you actually read anything Rand ever wrote? Or did you get that idea purely from other people who also haven't read anything Rand ever wrote...
Comments
Post new comment